{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-044760","form_type":"8-K","ticker":"ENSC","cik":"0001716947","company_name":"Ensysce Biosciences, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.344667+00:00","generated_at":"2026-05-30T02:02:49.028866+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ensysce reports Q3 net income of $0.7M; awarded $14M NIH grant for PF614-MPAR","bullets":["Net income of $0.7M vs net loss of $2.7M in Q3 2023; driven by $3.4M in federal grant revenue.","Cash & equivalents $4.2M at Sept 30, 2024, up from $1.1M at Dec 31, 2023; $8.5M raised in equity financings.","Awarded $14M multi-year NIH grant for PF614-MPAR; second Phase 1b trial initiated.","Pivotal PF614 Phase 3 protocol submitted to FDA; feedback expected by end of November.","Stockholders' equity $6.6M, compliant with Nasdaq $2.5M listing requirement."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-044760","json":"https://secwatch.observer/filing/0001493152-24-044760.json","markdown":"https://secwatch.observer/filing/0001493152-24-044760.md","text":"https://secwatch.observer/filing/0001493152-24-044760.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716947/000149315224044760/0001493152-24-044760-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716947/000149315224044760/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:02:49.028866+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}